Research status of pharmacological mechanism of PCSK9 inhibitors and discussion of their clinical application
10.13699/j.cnki.1001-6821.2024.16.029
- VernacularTitle:PCSK9抑制药的药理作用机制研究现状及临床应用探讨
- Author:
Wen-Hui MO
1
,
2
;
Si-Lei XU
;
Xia HE
;
Niu-Niu BAI
;
Meng-Ying YUAN
;
Zhi-Min LI
;
Jiao ZHANG
;
Fei WANG
;
Yuan-Kun ZHENG
Author Information
1. 四川省医学科学院·四川省人民医院药学部,四川成都 610072
2. 电子科技大学医学院个体化药物治疗四川省重点实验室,四川成都 610054
- Keywords:
Proprotein convertase subtilisin/kexin type 9 inhibitors;
atherosclerotic cardiovascular disease;
mechanism of action;
application status
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(16):2438-2441
- CountryChina
- Language:Chinese
-
Abstract:
Atherosclerosis caused by disorders of lipid metabolism is the main pathological basis of atherosclerotic cardiovascular disease.Statins are the cornerstone of lipid-modulating therapy for this type of disease,but in practice there are still some patients with suboptimal lipid management.Proprotein convertase subtilisin/kexin type 9(PCSK9)inhibitors have been gradually applied as a new class of lipid-modulating drugs for the treatment in patients with this type of disease,and recent studies have shown that in addition to regulating lipid metabolism,PCSK9 inhibitors also have potential anti-inflammatory and anti-platelet activation effects.This article sorts out the multiple pharmacological mechanisms of action of PCSK9 inhibitors and the current status of clinical research of PCSK9 inhibitors.Besides,it discusses the factors that may affect the efficacy of PCSK9 inhibitors,in order to provide a reference for the safe and rational medication of PCSK9 inhibitors.
